Final hours! Save up to 55% OFF InvestingProCLAIM SALE

HSBC is bullish on Biopharma stocks

Published 14/07/2023, 10:58 pm
© Reuters.
LLY
-
PFE
-
BMY
-
MRNA
-

HSBC analysts initiated research coverage of Biopharma stocks with a predominantly positive view.

The analysts argue that “a loss of exclusivity and drug pricing regulations are likely to accelerate the industry’s capital allocation towards M&A and licencing deals.”

Along these lines, the analysts prefer companies with strong balance sheets, limited loss of exclusivity exposure, and a strong R&D culture.

HSBC started coverage of 19 large-cap U.S. and European Biopharma stocks, including 14 Buys, 4 Reduces, and 1 Hold rating.

Among the Buy-rated stocks, the analysts highlighted “quality growth” names like Eli Lilly (NYSE:LLY) or “value” players like Pfizer (NYSE:PFE).

“LLY is set to benefit from Mounjaro’s stronger data in obesity. Its early stage data in obesity data on retatrutide shows even greater promise, though its phase III evidence will be critical to validate such expectations,” they said in a note.

On Pfizer, they added:

“With management ambition to outgrow its LOE phase through 2025-30, the company has acquired ADC platform company Seagen, on a fair value on our calculations. This puts it in a comfortable position where it can show capital discipline for future deals.”

On the other hand, they started Bristol-Myers Squibb (NYSE:BMY) with a Reduce rating as the market might put multiples under further pressure over the next three years.

Similarly, Moderna (NASDAQ:MRNA) is a new Reduce at HSBC as analysts see “further downside risk to Moderna’s COVID-19 vaccine revenue estimates.”

“Whilst Merck & Co and Moderna are sufficiently convinced by the phase II clinical data for the cancer vaccine to spend more money on next phase of development, we think that the data was less convincing than the company’s commentary suggested (see Moderna section for our discussion of the data),” the analysts concluded.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.